UroToday

SUO 2025: Trials in Progress - The GAIN Trial (ALLIANCE A032303): Gemcitabine Alternating with Intravesical BCG Randomization Against BCG Alone for Patients with Recurrent ...

(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Eugene Pietzak discussing the GAIN trial assessing gemcitabine ...
UroToday

ESMO 2025: IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

(UroToday.com) The 2025 ESMO annual meeting featured a Presidential Symposium session and a presentation by Dr. Thomas B. Powles discussing results from IMvigor011, a phase 3 trial of ctDNA-guided ...
UroToday

SUO 2025: Efficacy of Rucaparib vs Physician’s Choice in Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer by Age: Results from the TRITON3 Study

SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.
UroToday

ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations ...

San Francisco, California (UroToday.com) The PROfound Study is the first positive randomized Phase 3 study in a molecularly-defined population of patients with metastatic castration-resistant prostate ...
UroToday

ESMO 2025: Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a Phase II Trial of a Novel RNAseq-based ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany, between October 17 th and 21 st, 2025, was host to a renal and urothelial carcinoma ...
UroToday

ESMO 2025: Neoadjuvant Darolutamide + ADT for High/very-High Risk Locally Advanced Prostate Cancer: A Multi-Center, Open Label, Single Arm, Phase 2 Trial

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Kaiwei Yang discussing a phase 2 trial assessing neoadjuvant darolutamide + ADT for ...
UroToday

REVELUTION Trial: A Comparative Study of GnRH Agonist and Antagonist on Coronary Plaque in Prostate Cancer - Sagar Patel

Sagar Patel presents the REVELUTION trial comparing leuprolide versus relugolix effects on coronary plaque progression in 94 men with non-metastatic prostate cancer receiving pelvic radiotherapy.
UroToday

Non-Muscle Invasive Bladder Cancer

ESMO 2024, High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC), Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically, catumaxomab (CAT), EpCAM+ tumor cells.
UroToday

AUA 2022: AUA Guidelines: Localized Prostate Cancer

Clinicians should use clinical T stage, serum prostate-specific antigen (PSA), Grade Group (Gleason score), and tumor volume on biopsy to risk stratify patients with newly diagnosed prostate cancer.
UroToday

ASCO 2025: ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) plus Androgen-Deprivation Therapy (ADT) in Patients (Pts) with Metastatic Hormone ...

ASCO 2025 overall survival analysis of enzalutamide plus androgen-deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC), ARCHES study.
UroToday

ESMO 2023: Effect of Rapid Ultra-Low Prostate-Specific Antigen Decline (UL PSA) in TITAN Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Who Received ...

(UroToday.com) The 2023 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain between October 20 th and 24 th, 2023 was host to a prostate cancer abstracts poster session.
UroToday

ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition)

ESMO 2025, PSMA-positive metastatic hormone-sensitive prostate cancer, [177Lu]Lu-PSMA-617, VISION trial, PSMAfore trial, PSMAddition trial, 68Ga-PSMA-11 PET/CT.